این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
The Archives of Bone and Joint Surgery، جلد ۱۰، شماره ۱۱، صفحات ۹۴۶-۹۶۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic
چکیده انگلیسی مقاله risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the effectiveness of usingcombined conventional and biological disease-modifying anti-rheumatic drugs(bDMARDs) in managing rheumaticdiseases, there have been concerns that taking biological agents may have an additive effect on getting infected withCOVID-19. This study evaluates the impact of taking biological agents on altering the chance of getting infected withSARS-CoV-2 in rheumatoloid and lupus patients compared to traditional DMARDs.Methods: We carried out a cross-sectional survey study from February 2020 to January 2021 on patients diagnosedwith lupus and rheumatid arthritis. COVID-19 infection was confirmed by the presence of symptoms and signs of the diseaseand para-clinical findings such as lymphopenia and elevated C-reactive protein (CRP) and positive chest CT scanor polymerase chain reaction (PCR) of COVID-19.Results: Out of 591 patients included in this study, 422 (71.4%) had rheumatoid arthritis (RA), and 169 (28.6%) hadsystemic lupus erythematosus (SLE). Among them, 56 (9.5%) cases were diagnosed with COVID-19 infection. Noassociation was found between age, gender, or type of rheumatological diseases and SARS-CoV-2. There was asignificant association between COVID-19 infection and treatment with biological drugs (P-value< 0.05) regardless ofthe type of rheumatologic disease. Interestingly, the analysis revealed that the type of biologic drug also altered thechance of COVID-19 infection; In fact, patients who took TNF inhibitors were significantly at a higher risk of diseasethan those taking Rituximab (P-value=0.000). Identical results were observed among RA patients (P-value< 0.001),however, all 5 (3%) lupus cases treated with Rituximab infected with covid 19.Conclusion: This study develops a better understanding of the risk of immunosuppressive medications for SARSCoV-2 infection. Patients treated with conventional and biological medicine had a higher disease risk than those takingexclusively conventional drugs. However, more studies are required to deliberate the relation of the reviewed factorswith the severity of COVID-19.Level of evidence: II
کلیدواژه‌های انگلیسی مقاله Anti-TNFs, biological DMARDs, COVID-19, Adalimumab, Infliximab, Rituximab, Rheumatoid Arthritis (RA), Systemic Lupus Erythematous (SLE), Altebrel, CinnoRA
نویسندگان مقاله | Maryam Sahebari
Rheumatic Diseases Research Center (RDRC), Mashhad Universality of Medical Sciences, Mashhad, Iran


| Zahra Mirfeizi
Rheumatic Diseases Research Center (RDRC), Mashhad Universality of Medical Sciences, Mashhad, Iran


| Kamila Hashemzadeh
Rheumatic Diseases Research Center (RDRC), Mashhad Universality of Medical Sciences, Mashhad, Iran


| Ensie Salavati Nik
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


| Negar Gholampoor Shamkani
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
نشانی اینترنتی https://abjs.mums.ac.ir/article_21146.html
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده RESEARCH PAPER
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات